48 related articles for article (PubMed ID: 26818574)
1. Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Naren D; Wu J; Gong Y; Yan T; Wang K; Xu W; Yang X; Shi F; Shi R
Leuk Res; 2016 Mar; 42():59-67. PubMed ID: 26818574
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane molecular pump activity of Niemann-Pick C1 protein.
Davies JP; Chen FW; Ioannou YA
Science; 2000 Dec; 290(5500):2295-8. PubMed ID: 11125140
[TBL] [Abstract][Full Text] [Related]
3. Niemann-Pick C heterozygosity confers resistance to lesional necrosis and macrophage apoptosis in murine atherosclerosis.
Feng B; Zhang D; Kuriakose G; Devlin CM; Kockx M; Tabas I
Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10423-8. PubMed ID: 12923293
[TBL] [Abstract][Full Text] [Related]
4. An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor.
Ahmad I; Fatemi SN; Ghaheri M; Rezvani A; Khezri DA; Natami M; Yasamineh S; Gholizadeh O; Bahmanyar Z
Cell Commun Signal; 2023 Dec; 21(1):352. PubMed ID: 38098077
[TBL] [Abstract][Full Text] [Related]
5. Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles.
Eltoukhy AA; Sahay G; Cunningham JM; Anderson DG
ACS Nano; 2014 Aug; 8(8):7905-13. PubMed ID: 25010491
[TBL] [Abstract][Full Text] [Related]
6. CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells.
Xing C; Xu W; Shi Y; Zhou B; Wu D; Liang B; Zhou Y; Gao S; Feng J
Mol Med Rep; 2020 Oct; 22(4):2791-2800. PubMed ID: 32945456
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.
Wei D; Liang X; Huang M; Wang C; Ye Z; Zhang T; Zhang J
Ann Hematol; 2024 Jun; ():. PubMed ID: 38847852
[TBL] [Abstract][Full Text] [Related]
8. Baculovirus Utilizes Cholesterol Transporter NIEMANN-Pick C1 for Host Cell Entry.
Li Z; Fan Y; Wei J; Mei X; He Q; Zhang Y; Li T; Long M; Chen J; Bao J; Pan G; Li C; Zhou Z
Front Microbiol; 2019; 10():2825. PubMed ID: 31866985
[TBL] [Abstract][Full Text] [Related]
9. NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer.
O'Neill KI; Kuo LW; Williams MM; Lind H; Crump LS; Hammond NG; Spoelstra NS; Caino MC; Richer JK
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884604
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of NPC1 and its association with poor prognosis in gastric cancer.
Tang W; Huang J; Li G; Zhou Z; Wang Z
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38698279
[TBL] [Abstract][Full Text] [Related]
11. Urinary Metabolic Distinction of Niemann-Pick Class 1 Disease through the Use of Subgroup Discovery.
Carmona CJ; German-Morales M; Elizondo D; Ruiz-Rodado V; Grootveld M
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887404
[TBL] [Abstract][Full Text] [Related]
12. Erratum for the Report "Transmembrane molecular pump activity of Niemann-Pick C1 protein," by J. P. Davies
Science; 2024 May; 384(6696):eadq2125. PubMed ID: 38723098
[No Abstract] [Full Text] [Related]
13. Expression of Penaeus monodon ortholog of Niemann-Pick type C-2 in the spermatic tract, and its role in sperm cholesterol removal.
Chotwiwatthanakun C; Sangatit J; Santimanawong W; Surinlert P; Prommoon J; Weerachatyanukul W; Withyachumnarnkul B; Vanichviriyakit R
Mol Reprod Dev; 2016 Mar; 83(3):259-70. PubMed ID: 26822874
[TBL] [Abstract][Full Text] [Related]
14. The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.
Wang H; Tam YY; Chen S; Zaifman J; van der Meel R; Ciufolini MA; Cullis PR
Mol Ther; 2016 Dec; 24(12):2100-2108. PubMed ID: 27633442
[TBL] [Abstract][Full Text] [Related]
15. Optimization of miRNA delivery by using a polymeric conjugate based on deoxycholic acid-modified polyethylenimine.
Radmanesh F; Abandansari HS; Pahlavan S; Alikhani M; Karimi M; Rajabi S; Kazemi B; Baharvand H
Int J Pharm; 2019 Jun; 565():391-408. PubMed ID: 31085260
[TBL] [Abstract][Full Text] [Related]
16. Bioreducible PEI-functionalized glycol chitosan: A novel gene vector with reduced cytotoxicity and improved transfection efficiency.
Taranejoo S; Chandrasekaran R; Cheng W; Hourigan K
Carbohydr Polym; 2016 Nov; 153():160-168. PubMed ID: 27561483
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of recombinant human thrombopoietin on clinical outcomes in CD7-positive and CD7-negative acute myeloid leukaemia.
Sun X; Bai Y; Li M; Li W; Wang H; Xiao M; Dou L; Song J; Niu J; Xiao X; Chen Y; Sun K
Leuk Res; 2023 May; 128():107034. PubMed ID: 36906940
[TBL] [Abstract][Full Text] [Related]
18. An immune risk score predicts survival of patients with diffuse large B-cell lymphoma.
Zhu Y; Xiao H; Yu T; Cai D; Zhou Q; Zhou G; Wang L
Leuk Res; 2023 Feb; 125():107008. PubMed ID: 36630885
[TBL] [Abstract][Full Text] [Related]
19. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
Zhang Y; Liu C; Zhang R; Shi Y; Li X; Yu J; Wan D; Xie X
Leuk Res; 2023 Jan; 124():106997. PubMed ID: 36502583
[TBL] [Abstract][Full Text] [Related]
20. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.
Li L; Cui Y; Shen J; Dobson H; Sun G
Leuk Res; 2019 Mar; 78():12-20. PubMed ID: 30660961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
